Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Trastuzumab Combo Paves Way for Novel Regimens in HER2+ Uterine Serous Carcinoma

April 28th 2020

Amanda Nickles Fader, MD, discusses the rationale for a phase II study and explains how the findings could open the door to other treatment options for women with uterine serous carcinoma.

Dostarlimab Active in dMMR Endometrial Cancer

April 25th 2020

The PD-1 inhibitor dostarlimab demonstrated clinically meaningful activity in patients with mismatch repair–deficient endometrial cancer.

Dr. Pothuri on the Importance of Obtaining Patient-Reported Outcomes in Ovarian Cancer

April 24th 2020

Bhavana Pothuri, MD, discusses the importance of obtaining patient-reported outcomes in ovarian cancer.

Dr. Fader on Trastuzumab/Chemo in HER2+ Uterine Serous Carcinoma

April 24th 2020

Amanda Nickles Fader, MD, discusses the utility of trastuzumab plus chemotherapy in HER2-positive uterine serous carcinoma.

Observing Optimal Treatment Strategies in Ovarian Cancer in Ohio

April 23rd 2020

We recently traveled to Columbus, Ohio for a State of the Science Summit™ on Ovarian Cancer, which featured insights from The Ohio State University Comprehensive Cancer Center–James faculty.

Dr. Swisher on the Limitations of HRD as a Biomarker in Ovarian Cancer

April 23rd 2020

Elizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.

FDA Approves New Use for cobas HPV Cervical Cancer Screening Test

April 21st 2020

The cobas HPV test for cervical cancer screening is now FDA-approved for use on the high-throughput cobas 6800/8800 Systems.

Niraparib Granted Priority Review in China for Frontline Maintenance in Ovarian Cancer

April 16th 2020

The China National Medical Products Administration has granted a priority review to niraparib for use as a frontline maintenance treatment for adult patients with advanced ovarian cancer.

Dr. Fader on the Rationale for Targeting HER2/neu in Uterine Serous Carcinoma

April 15th 2020

Amanda Nickles Fader, MD, discusses the rationale for utilizing HER2/neu as a target in uterine serous carcinoma.

Margarett C. Ellison, MD of Gynecologic Oncology of Tallahassee Joins Florida Cancer Specialists and Research Institute

April 15th 2020

Florida Cancer Specialists & Research Institute is pleased to announce the addition of gynecologic-oncologist Dr. Margarett C. Ellison in Tallahassee.

Dr. Chase on Toxicities With Niraparib in Ovarian Cancer

April 11th 2020

Dana Chase, MD, FACOG, discusses the safety profile of niraparib as frontline maintenance therapy in ovarian cancer.

Addition of Trastuzumab to Chemo Boosts Survival in HER2+ Uterine Serous Carcinoma

April 10th 2020

The addition of trastuzumab to carboplatin and paclitaxel resulted in a significant survival benefit in women with advanced or recurrent, HER2-positive uterine serous carcinoma, with the greatest benefit observed in those with stage III/IV disease who received the regimen up front.

Dr. Fader on Adding Trastuzumab to Chemo in HER2+ Uterine Serous Carcinoma

April 9th 2020

Amanda Nickles Fader, MD, discusses findings from a randomized phase II trial examining the efficacy of adding trastuzumab to carboplatin/paclitaxel in patients with advanced or recurrent uterine serous carcinomas that overexpress HER2/neu.

Dr. Gunderson on the Use of PARP Inhibitors in All-Comers With Ovarian Cancer

April 9th 2020

Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the use of PARP inhibitors in all-comers with ovarian cancer.

Palliative Care Study Suggests Benefits for Patients With Cervical Cancer

April 9th 2020

Alexandra S. Bercow, MD, discusses the implications of research showing that patients with advanced-stage cervical cancer who received palliative care consultations underwent the same level of treatment but had shorter, less acute, and fewer hospital stays than their counterparts who were not given such referrals.

Pazopanib Plus Oral Cyclophosphamide Shows Benefit in Platinum-Resistant Epithelial Ovarian Cancer

April 9th 2020

Pazopanib plus oral cyclophosphamide is a well-tolerated regimen that has clinically relevant benefit in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a retrospective study published in the Journal of Clinical Oncology.

FDA Grants Balstilimab Fast Track Designation for Cervical Cancer

April 8th 2020

The FDA has granted the PD-1 inhibitor balstilimab a Fast Track Designation for the treatment of patients with cervical cancer.

Dr. Coffman on Safety Concerns With PARP Inhibitors in Ovarian Cancer

April 7th 2020

Lan G. Coffman, MD, PhD, assistant professor at the University of Pittsburgh Medical (UPMC) Center Hillman Cancer Center, discusses safety concerns with PARP inhibitors in ovarian cancer.

Unique Aspects of Cancer Surgery Make Clinical Trials Challenging

April 7th 2020

The conduct of randomized trials in surgical oncology, although highly appealing in concept, may be problematic, especially in complex settings where the skills, experience, and clinical judgment of individual surgeons and their institutions may vary greatly.

Dr. Penson on Re-Challenging With PARP Inhibition in Ovarian Cancer

April 4th 2020

Richard T. Penson, MD, MRCP, associate professor of medicine, Harvard Medical School, and clinical director of Medical Gynecologic Oncology, in the Department of Medicine, Massachusetts General Hospital, discusses re-challenging with PARP inhibition in patients with ovarian cancer.